Psychopharmacology

What is the effect of cannabis use on adherence to medications in patients with psychosis?

From the at-home ketamine experience to the Wit v United Behavioral Health reversal, here are highlights from the week in Psychiatric Times.

"As clinicians who took an oath to 'do no harm,' we must educate the public about the dangers and non–standard of care of the growing practice of at-home ketamine."

Researchers performed a nationwide cohort study of the use of calcium-channel blockers and adenosine modulators and risk of hospitalization in bipolar disorder.

From older age bipolar disorder to the relationship between antidepressants and emotional numbing, here are highlights from the week in Psychiatric Times.

The experts weighed in on a wide variety of psychiatric issues for the September 2022 issue of Psychiatric Times.

From ketamine response to differences between mTBI and concussion, here are highlights from the week in Psychiatric Times.

Will it hurt my baby? Researchers investigated associations between first trimester exposure to second-generation antipsychotics and major congenital malformations.

The underlying neural mechanisms identified may help clinicians better understand ketamine response in human patients.

Risk of suicide attempt is higher among adults, women.

"It would be naïve to believe that targeting a single neurotransmitter, receptor, or circuit in the brain will cure any psychiatric or neurological disorder. However, we would be remiss if we did not try."

What lead to this teen being prescribed 10 psychiatric drugs and why is it a symptom of a larger problem?

What is the optimal dose of aripiprazole as augmentation for treatment-refractory depression? Researchers performed a systematic review and dose-effect meta-analysis.

Getting the “NAC” of treating negative symptoms: Researchers performed a randomized controlled trial of N-acetylcysteine in clozapine-resistant schizophrenia.

Researchers discuss new research on buprenorphine, the “gold standard” treatment for opioid use disorder at the APA Annual Meeting.

Interim study results show 77% treatment response rate among participants.

Investigators observed higher levels of depression in children and adolescents with ADHD during MPH treatment.

Top-line data for study is expected in late 2022, early 2023.

Approval comes 1 year after the drug was approved for the treatment of ADHD in children and adolescents.

The warnings cite consumer risks, as well as FD&C, RHA violations.

Here are a few reminders to help avoid both toxicity and loss of effectiveness.

Research is underway to make psychedelics agents a treatment option for psychiatric disorders.

Research also finds surprising results in patients with bipolar affective disorder.

Results highlight the impact of education on patient understanding of potential adverse events.

Drug comparison has significant implications for dose- and substance-dependence.